IMAGO BIOSCIENCES INC (IMGO) Stock News
NASDAQ:IMGO - Nasdaq - US45250K1079 - Common Stock - Currency: USD
IMGO Latest News, Press Relases and Analysis
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.
Looking Into Imago BioSciences's Recent Short Interest
Imago BioSciences's (NASDAQ:IMGO) short percent of float has risen 41.79% since its last report. The company recently reported that it has 1.00 million shares sold short, which is 3.97% of all regular shares that are available for trading.
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Merck is best performing large U.S. pharma of 2022 (NYSE:MRK)
Merck (MRK) shareholders have much to celebrate as the company is the best performing large US pharma of 2022 with a return of more than 43% this year.One of the Merck's (MRK)...
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage...
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to...
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom...
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Mentions: MRK
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company...
3 Dow Stocks to Take Seriously in 2023
The top Dow stocks for 2023 are all big free cash flow generators that ought to be able to cope with whatever next year brings.
SHAREHOLDER ALERT: Weiss Law Investigates Imago BioSciences, Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Imago BioSciences, Inc....
Mentions: MRK
Shareholder Alert: Ademi LLP investigates whether Imago BioSciences, Inc. has obtained a Fair Price in its transaction with Merck
/PRNewswire/ -- Ademi LLP is investigating Imago (Nasdaq: IMGO) for possible breaches of fiduciary duty and other violations of law in its transaction with...